Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
WALTHAM, Mass., March 28, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
